Loading...

Home
Stock
ABBV

ABBV Overview

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

Loading chart...

High

229.289

Open

226.050

VWAP

227.42

Vol

5.30M

Mkt Cap

402.58B

Low

225.295

Amount

1.21B

EV/EBITDA(TTM)

15.77

Total Shares

1.77B

EV

464.86B

EV/OCF(TTM)

24.43

P/S(TTM)

6.60

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

Show More

Events Timeline

(ET)

2026-03-09

08:10:00

AbbVie Reports Positive Results for ABBV-295 Clinical Trial

2026-03-02 (ET)

2026-03-02

12:00:00

AbbVie's Neuroendocrine Carcinoma Treatment Receives FDA Orphan Designation

2026-03-02

08:40:00

AbbVie Reports Positive Results from Crohn's Disease Study

2026-02-26 (ET)

2026-02-26

10:20:00

AtaiBeckley Reports Phase 2 Results for EMP-01 in Social Anxiety Disorder

2026-02-23 (ET)

2026-02-23

11:10:00

AbbVie Announces $380M Investment for New Drug Manufacturing Facilities

2026-02-23

06:10:00

Ideaya Biosciences Appoints Theodora Ross as Chief Development Officer

2026-02-20 (ET)

2026-02-20

05:10:00

AbbVie Receives FDA Approval for New Drug Combination to Treat CLL

News

seekingalpha

03-11seekingalpha

PinnedUCB's Bimzelx Outperforms AbbVie's Skyrizi in Psoriatic Arthritis Trial

Clinical Trial Success: UCB's Bimzelx achieved the primary endpoint ACR50 in the BE BOLD trial for psoriatic arthritis, demonstrating over 50% improvement and indicating its superiority over AbbVie's Skyrizi, which could significantly enhance UCB's competitive position in the biopharmaceutical market.
Patient Recruitment: The trial enrolled over 500 adults with active psoriatic arthritis, ensuring the reliability and broad applicability of the data, thereby strengthening Bimzelx's market recognition as an effective treatment option.
Good Safety Profile: UCB reported that Bimzelx has a well-tolerated safety profile with no new safety signals, providing strong support for its market promotion and patient acceptance, which may drive future sales growth.
Broad Market Prospects: This trial marks the fourth head-to-head study showing Bimzelx's superiority in psoriatic disease and the first in PsA, indicating UCB's ongoing innovation capabilities and market potential in this therapeutic area.

Fool

Investment Opportunities Amid Market Volatility

AbbVie's Defensive Nature: AbbVie boasts a vast portfolio of medicines, and despite economic downturns, the demand for therapies addressing chronic autoimmune diseases and cancer remains strong, ensuring stable revenue and earnings, thus providing investors with a sense of security during market declines.
AbbVie's Dividend King Status: As a Dividend King with 50 consecutive years of dividend increases, AbbVie demonstrates its ability to maintain dividend payments even in tough economic times, helping investors smooth out losses and enhancing its appeal amid market volatility.
Microsoft's Stable Revenue: Although Microsoft operates in a cyclical industry, its office software products are integral to daily life for individuals and businesses, allowing it to maintain a steady revenue stream even during economic recessions, showcasing the resilience of its business model.
Growth Potential in Cloud and AI: Microsoft's leadership in cloud computing and artificial intelligence provides strong growth prospects, and while it may face challenges during economic slowdowns, investors can still expect superior returns in the long run, making it an attractive investment opportunity.

CNBC

Dublin Data Center First to Use Independent Microgrid in Europe

Microgrid Innovation: The Dublin facility, a collaboration between AVK and Pure Data Centre Group, establishes Europe's first independent microgrid data center with an estimated total investment of €1 billion, aimed at addressing power connection delays and promoting sustainable development in data centers.
Rising Energy Demand: The European Commission estimates that by 2040, at least €1.2 trillion will be needed to meet growing energy demands, with data centers consuming 22% of Ireland's power in 2024, highlighting their pressure on the national grid.
Policy Changes Impact: The Irish government has eased the moratorium on new data center applications, mandating that new facilities provide dispatchable power or energy storage capacity, which promotes the adoption of microgrids and reflects a reassessment of the AI industry's potential.
Market Growth Potential: The global microgrid market is projected to reach $29 billion by 2025, with Europe's market expected to grow nearly 10% annually, providing new investment opportunities for companies like AVK and driving technological advancements in the data center sector.

CNBC

Investment Opportunities in Biotech Stocks

AbbVie Financial Performance: In 2025, AbbVie achieved full-year revenues of $61.2 billion, an 8.6% year-over-year increase, with the ex-Humira growth platform accelerating to 14.5% in Q4, indicating strong growth potential in immunology and oncology.
Technical Support Analysis: AbbVie shares are currently trading around $230, comfortably above the 50-day moving average and near the 200-day moving average, which serves as a critical support level; maintaining above this level could sustain the long-term uptrend, while a breach may signal a technical pullback risk.
Amgen Revenue Growth: In 2025, Amgen reported revenues of $36.8 billion, a 10% year-over-year increase, with 18 products achieving record sales, showcasing its competitive strength in cardiovascular, bone health, and oncology markets.
Market Trend Observation: Amgen's stock is currently pulling back towards the 50-day moving average; if it finds support around $352, it could present a lower-risk entry point for investors, whereas a drop below the 200-day moving average may indicate a more significant trend reset.

NASDAQ.COM

03-09NASDAQ.COM

SPYM ETF 52-Week Price Analysis

Price Range Analysis: SPYM ETF's 52-week low is $56.6699 and high is $82.1079, with the latest trade at $78.12, indicating significant price fluctuations over the past year that can help investors assess market performance.
Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides investors with deeper technical insights, aiding in more informed investment decisions, although the specific 200-day moving average value is not mentioned in the article.
ETF Unit Trading Mechanism: ETFs trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, providing high liquidity in the market.
Monitoring Inflows and Outflows: Weekly monitoring of changes in ETF units focuses on notable inflows (new units created) or outflows (old units destroyed), with these dynamics potentially impacting not only the ETF itself but also the individual stocks held within it.

Benzinga

AbbVie Shares Dip Following Phase 1 Study Results of ABBV-295

Obesity Drug Progress: AbbVie reported in its Phase 1 study that ABBV-295 demonstrated clinically meaningful, dose-dependent weight reductions, with mean percentage changes ranging from -7.75% to -9.79% at week 12, highlighting the drug's potential despite overall market pressures.
Market Performance Pressure: AbbVie shares fell 0.25% to $229.52 amid a broader market decline, although the stock has increased by 6.06% over the past 12 months, indicating a strong long-term trend.
Technical Analysis Signals: The stock is currently trading 0.4% above its 20-day simple moving average (SMA) and 1.5% above its 100-day SMA, suggesting some short-term strength, but with an RSI of 53.14 indicating neutral territory, caution is advised for investors.
Analyst Ratings Optimistic: Despite stock fluctuations, AbbVie holds a “Buy” rating with an average price target of $241.24, with recent positive targets set by RBC Capital and Barclays, reflecting market confidence in its future performance.

Wall Street analysts forecast ABBV stock price to rise

18 Analyst Rating

Wall Street analysts forecast ABBV stock price to rise

12 Buy

6 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

223.00

Averages

252.00

High

289.00

Current: 0.000

Low

223.00

Averages

252.00

High

289.00

RBC Capital

Trung Huynh

Outperform

initiated

$260

AI Analysis

2026-02-24

Reason

RBC Capital

Trung Huynh

Price Target

$260

AI Analysis

2026-02-24

initiated

Outperform

Reason

RBC Capital analyst Trung Huynh initiated coverage of AbbVie with an Outperform rating and $260 price target. The shares have underperformed on concerns AbbVie's "beat-and-raise" story is over and competition threatens its immunology growth, the analyst tells investors in a research note. RBC disagrees, saying AbbVie is still in early in indication expansion. It sees continued outperformance for the shares.

Barclays

Strong Buy

initiated

$275

2026-02-19

Reason

Barclays

Price Target

$275

2026-02-19

initiated

Strong Buy

Reason

Barclays initiated coverage of AbbVie with an Overweight rating and $275 price target. The firm believes consensus estimates are underestimating AbbVie's operating leverage potential. Barclays believes success in any of AbbVie's proof-of-concept studies can drive multiple expansion for the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABBV

Unlock Now

Valuation Metrics

The current forward P/E ratio for AbbVie Inc (ABBV.N) is 16.63, compared to its 5-year average forward P/E of 13.12. For a more detailed relative valuation and DCF analysis to assess AbbVie Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

13.12

Current PE

16.63

Overvalued PE

15.93

Undervalued PE

10.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

12.15

Current EV/EBITDA

14.93

Overvalued EV/EBITDA

14.12

Undervalued EV/EBITDA

10.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

4.91

Current PS

6.25

Overvalued PS

5.75

Undervalued PS

4.06

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

best stocks to swing trade

Intellectia · 1222 candidates

Region: USRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Month Price Change Pct: $-5.00 - $40.00Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Taiwan Semiconductor Manufacturing Co Ltd

1.94T

Exxon Mobil Corp

635.43B

Costco Wholesale Corp

448.66B

AbbVie Inc

410.36B

Procter & Gamble Co

390.70B

General Electric Co

358.95B

Intellectia · 59 candidates

Market Cap: >= 80.00BDividend Yield Ttm: 1 - 6Net Margin: >= 5.00Return On Equity: >= 10.0%Is Index Component: GSPC, DJI

Ticker

Name

Market Cap$

JPMorgan Chase & Co

809.92B

Exxon Mobil Corp

635.43B

Johnson & Johnson

598.69B

AbbVie Inc

410.36B

Procter & Gamble Co

390.70B

Home Depot Inc

379.01B

Stocks with same technicals as DHR

Intellectia · 52 candidates

Market Cap: >= 150.00BRegion: USRsi Category: moderateMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

NVIDIA Corp

4.31T

Apple Inc

3.88T

Alphabet Inc

3.77T

Broadcom Inc

1.52T

Tesla Inc

1.51T

Walmart Inc

1.02T

which are the s&p 500 companies

Intellectia · 476 candidates

Is Index Component: GSPC

Ticker

Name

Market Cap$

NVIDIA Corp

4.61T

Apple Inc

3.88T

Alphabet Inc

3.81T

Microsoft Corp

2.95T

Amazon.com Inc

2.26T

Meta Platforms Inc

1.66T

medical and tech

Intellectia · 1801 candidates

Sector: Financial Technology (Fintech) & Infrastructure, Healthcare, Healthcare Services & Equipment, Technology, Technology EquipmentList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

NVIDIA Corp

4.57T

Apple Inc

3.88T

Alphabet Inc

3.68T

Microsoft Corp

2.97T

Taiwan Semiconductor Manufacturing Co Ltd

1.88T

Meta Platforms Inc

1.63T

pe > 10 and macd golden cross

Intellectia · 1278 candidates

Pe Ttm: >= 10Macd: bullish

Ticker

Name

Market Cap$

Apple Inc

4.02T

Taiwan Semiconductor Manufacturing Co Ltd

1.88T

Broadcom Inc

1.61T

Berkshire Hathaway Inc

1.08T

Berkshire Hathaway Inc

1.08T

JPMorgan Chase & Co

866.44B

stocks to buy Monday

Intellectia · 297 candidates

Market Cap: >= 2.00BPrice: $5.00 - $300.00Quarter Revenue Yoy Growth: >= 10.0%Analyst Consensus: Strong Buy, Moderate BuyQuarter Eps Yoy Growth: >= 10.0%Moving Average Relationship: PriceAboveMA20, PriceAboveMA200

Ticker

Name

Market Cap$

NVIDIA Corp

4.49T

Apple Inc

4.07T

AbbVie Inc

395.82B

Advanced Micro Devices Inc

339.29B

AstraZeneca PLC

298.88B

Morgan Stanley

285.91B

show me stocks where congress has traded

Intellectia · 158 candidates

Congress Transactions: sale, purchase

Ticker

Name

Market Cap$

NVIDIA Corp

4.64T

Alphabet Inc

4.09T

Apple Inc

3.81T

Microsoft Corp

3.20T

Amazon.com Inc

2.56T

Meta Platforms Inc

1.81T

stocks with congressional trading data

Intellectia · 158 candidates

Congress Transactions: sale, purchase

Ticker

Name

Market Cap$

NVIDIA Corp

4.64T

Alphabet Inc

4.09T

Apple Inc

3.81T

Microsoft Corp

3.20T

Amazon.com Inc

2.56T

Meta Platforms Inc

1.81T

above 200 day sma

Intellectia · 3040 candidates

Moving Average Relationship: PriceAboveMA200

Ticker

Name

Market Cap$

NVIDIA Corp

4.45T

Alphabet Inc

3.96T

Apple Inc

3.64T

Amazon.com Inc

2.47T

Taiwan Semiconductor Manufacturing Co Ltd

1.69T

Broadcom Inc

1.56T

Whales Holding ABBV

Caisse des Dépôts et Consignations

ARS Investment Partners, LLC

Thornburg Investment Management, Inc.

Mubadala Investment Company PJSC

Jupiter Fund Management Plc

Caixa Econômica Federal

Trading Trends

Insider

Hedge Fund

Congress Trading

People Also Watch

Frequently Asked Questions

What is AbbVie Inc (ABBV) stock price today?

The current price of ABBV is 227.68 USD — it has increased 0.3

What is AbbVie Inc (ABBV)'s business?

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

What is the price predicton of ABBV Stock?

Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is252.00 USD with a low forecast of 223.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is AbbVie Inc (ABBV)'s revenue for the last quarter?

AbbVie Inc revenue for the last quarter amounts to 16.62B USD, increased 10.04

What is AbbVie Inc (ABBV)'s earnings per share (EPS) for the last quarter?

AbbVie Inc. EPS for the last quarter amounts to 1.02 USD, decreased -5200.00

How many employees does AbbVie Inc (ABBV). have?

AbbVie Inc (ABBV) has 57000 emplpoyees as of March 12 2026.

What is AbbVie Inc (ABBV) market cap?

Today ABBV has the market capitalization of 402.58B USD.